Literature DB >> 108971

Osteoblastic response to successful treatment of metastatic cancer of the prostate.

J J Pollen, W J Shlaer.   

Abstract

Increasing sclerosis of bone in patients with prostatic cancer most commonly is associated with disease progression. In a study of serial radiographs in a group of 18 patients who experienced objective clinical remission after treatment of metastatic cancer of the prostate, eight (44%) showed an osteoblastic response as part of their healing reaction to successful therapy. The importance of a blastic response as a possible sign of clinical improvement is emphasized. Clinical, biochemical, and bone scan correlations are discussed as they apply to patients who respond favorably to treatment of metastatic cancer of the prostate.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 108971     DOI： 10.2214/ajr.132.6.927

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  13 in total

1.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

Authors:  Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Radiosurgery for metastatic spinal tumors: follow-up MR findings.

Authors:  Y J Hwang; M-J Sohn; B H Lee; S Y Kim; J W Seo; Y H Han; J Y Lee; S J Cha; Y H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-27       Impact factor: 3.825

3.  Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Authors:  Mehmet Asim Bilen; Marcella M Johnson; Paul Mathew; Lance C Pagliaro; John C Araujo; Ana Aparicio; Paul G Corn; Nizar M Tannir; Franklin C Wong; Michael J Fisch; Christopher J Logothetis; Shi-Ming Tu
Journal:  Cancer       Date:  2014-08-22       Impact factor: 6.860

4.  Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Authors:  Connie Y Chang; F Joseph Simeone; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2017-06-30       Impact factor: 2.199

5.  The flare phenomenon: far from fair and square.

Authors:  W D van Schelven; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-05

6.  False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature.

Authors:  Yi-Shan Yu; Wan-Hu Li; Ming-Huan Li; Xue Meng; L I Kong; Jin-Ming Yu
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

Review 7.  Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

Authors:  Shi-Ming Tu; Sue-Hwa Lin; Donald A Podoloff; Christopher J Logothetis
Journal:  Clin Adv Hematol Oncol       Date:  2010-05

8.  Follow-up CT and MR findings of osteoblastic spinal metastatic lesions after stereotactic radiotherapy.

Authors:  Yoon Joon Hwang
Journal:  Jpn J Radiol       Date:  2012-04-12       Impact factor: 2.374

Review 9.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

10.  Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Authors:  Joerg Stattaus; Steffen Hahn; Thomas Gauler; Wilfried Eberhardt; Stefan P Mueller; Michael Forsting; Susanne C Ladd
Journal:  Eur Radiol       Date:  2008-08-02       Impact factor: 5.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.